Radioactive drug trial offers new hope for advanced prostate cancer

NCT ID NCT06879041

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study testing a new radioactive drug called AZD2284 in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to find a safe and tolerable dose. Researchers will also use imaging to see how the drug travels in the body and if it helps shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Palo Alto, California, 94304, United States
Research Site
RECRUITING

Miami, Florida, 33165, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
NOT_YET_RECRUITING

Metairie, Louisiana, 70006, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
NOT_YET_RECRUITING

Rochester, Minnesota, 55902, United States
Research Site
RECRUITING

Omaha, Nebraska, 68130, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10032, United States
Research Site
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Research Site
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

East Melbourne, 3002, Australia
Research Site
NOT_YET_RECRUITING

CapeTown, 7925, South Africa
Research Site
WITHDRAWN

Durban, 4013, South Africa
Research Site
NOT_YET_RECRUITING

Pretoria, 181, South Africa

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER